Taletrectinib Has Meaningful Clinical Efficacy in ROS1+ NSCLC

Taletrectinib can produce durable responses in patients with ROS1-positive non-small cell lung cancer, a phase 2 trial suggests.

Related Keywords

China ,Tongji ,Sichuan ,Shanghai ,Wei Li ,European Lung Cancer Congress ,Shanghai Pulmonary Hospital ,Thoracic Cancer Institute ,Tongji University School ,Clinical Trials Identifier ,